Prof Sagar Lonial (Emory University, Atlanta, USA), Prof Meral Beksaç (University of Ankara, Ankara, Turkey) and Dr Robert Rifkin (Rocky Mountain Cancer Centers, Denver, USA) discuss the results from the US MM-6 study, along with the challenges associated with the long-term treatment of patients with newly diagnosed multiple myeloma (NDMM). This study was conducted in community-based oncology settings, where real-world treatment patterns were observed.
Dr Rifkin gives an overview of the US MM-6 study and explains the unique design of the study, which evaluated the transition from bortezomib to ixazomib in these patients. He discusses the main results from this study, which assessed patient quality of life and mentions that this treatment was well-tolerated and achieved a compliance rate of more than 90 percent.
Prof Beksaç highlights the current treatment landscape of these patients in Europe and the panel discuss some of the treatment challenges – especially in the older and frail population.
The panel emphasise that the use of real-world data presents an accurate reflection of this patient population and similar studies in this area are needed. Dr Rifkin mentions that this study will be expanded in the future, with the addition of European centres.
This programme has been supported by an unrestricted educational grant from Takeda.
|Background of the US MM-6 study|
|Results of the US MM-6 study|
|Tolerability and safety of the IRd regimen|
|Implications of the real-world study design|
|Current treatment landscape in Europe|
|Challenges of long-term treatment|
|Evaluating quality of life data|
|Challenges in the management of MM patients|